NSCLC patients with low PD-1 expression in CD8+ cells after nivolumab treatment displayed a prolonged survival, indicating that CD8+; PD-1 low was a prediction factor for response to immunotherapy in NSCLC (Mazzaschi et al., 2018). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.